Table 3.
Prognostic factors of ovarian cancer from univariate and multivariate survival analysis.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Stage | 2.819 | 1.136–6.998 | 0.025* | 8.671 | 2.098–35.847 | 0.003* |
| III | ||||||
| IV | ||||||
| Grade | 1.191 | 0.525–2.568 | 0.656 | 2.532 | 0.972–6.591 | 0.057 |
| 1 | ||||||
| 2 | ||||||
| 3 | ||||||
| Ascites | 2.611 | 0.998–6.834 | 0.051 | 3.606 | 1.247–10.424 | 0.018* |
| Yes | ||||||
| No | ||||||
| p-ATR expression | 6.96 | 2.215–21.875 | 0.001* | 11.393 | 2.798–46.390 | 0.001* |
| Low | ||||||
| High | ||||||
| Histologic subtype | 0.941 | 0.702–1.261 | 0.683 | 0.865 | 0.647–1.157 | 0.329 |
| Serous | ||||||
| Squamous | ||||||
| Transitional cell | ||||||
| Serous and endometrioid | ||||||
| Endometroid | ||||||
| Endometroid and clear cell | ||||||
*
Statistically significant.
ATR, ataxia-telangiectasia and Rad3 related; CI, confidence interval; HR, hazard ratio; p-ATR, phospho-ATR ser428.